Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (MBOT) received a Canadian patent covering an adaptor that connects surgical tools to a motorized robotic surgical device.
The Canadian Intellectual Property Office grant brings its worldwide portfolio to 45 issued patents and 48 patent applications, including 21 issued patents in North America. The adaptor couples the proximal portion of tools such as guidewires and microcatheters to the robotic device. The company views patent protection as support for potential future market expansion and technology monetization, and says its portfolio gives it greater confidence to pursue regulatory clearances in additional markets beyond the U.S. and Israel.
Microbot Medical (Nasdaq: MBOT) secured its first office-based laboratory customer, ELMNT IR, through an order for LIBERTY robotic devices. The California outpatient interventional radiology practice signed an order to purchase up to a 12-month supply, becoming the company’s first West Coast customer. Office-based laboratories provide minimally invasive, image-guided procedures outside traditional hospitals.
ELMNT IR has already performed multiple procedures using LIBERTY. Microbot said every customer that has used its initial LIBERTY inventory has subsequently reordered additional systems. The geographic expansion aligns with the company’s Full Market Release strategy.
Microbot Medical (MBOT) announced that executives and commercial team members will attend SIR EDGE 2026 to engage with prospective customers. The conference is in Louisville, Kentucky, alongside the Association of Chiefs of Interventional Radiology Annual Fall Conference. The company sees an opportunity to meet hospital decision-makers and arrange demonstrations of its LIBERTY Endovascular Robotic System.
Microbot Medical (MBOT) received new patent approvals across the U.S., Japan, China and Canada, expanding its global intellectual property portfolio.
The company now holds 44 issued patents and 49 pending patent applications across North America, Europe, Israel and Asia. It continues expanding U.S. commercial adoption of its LIBERTY Endovascular Robotic System while pursuing a CE Mark for international expansion. Microbot expects its patent portfolio to expand over the coming months and links its intellectual property strategy to planned market entry into the EU and other jurisdictions.
Microbot Medical (MBOT) signed a three-year exclusive agreement with Medtechnica to market and sell its LIBERTY robotic system in Israel.
The system received regulatory approval from the Israeli Ministry of Health's AMAR Division and was registered in the Israeli Medical Device Registry in May 2026. Microbot anticipates initial orders under the agreement during the fourth quarter of 2026. The company also expects to enter additional markets and add distribution partners as it scales operations and expands manufacturing capacity. LIBERTY is FDA-cleared for peripheral endovascular procedures.
Microbot Medical (MBOT) reported its first California customer while outlining U.S. sales expansion at a September 24, 2026, analyst meeting.
The company is targeting 12 sales territories by year-end and is expanding in North Carolina. It hired three Area Sales Managers and one Regional Sales Director and is engaging hospital value analysis committees at multiple health systems. The company described a user survey as showing high satisfaction with its LIBERTY System.
Microbot expects manufacturing changes, including a second line, to produce positive gross margins in 2027. CE mark approval is expected in late Q4 2026 or early Q1 2027. Potential expansion into parts of Asia and the Middle East is in advanced stages.
Microbot Medical (Nasdaq: MBOT) filed its Form 10-Q for the quarter ended June 30, 2026 and reported that revenue and customer count increased by more than 100% versus the first quarter of 2026, driven by repeat orders, expanded utilization and new customers after the Full Market Release of the LIBERTY endovascular robotic system in mid-April.
According to Microbot Medical, procedure volume and the number of hospital sites using LIBERTY grew, with adoption extending to new health systems in Massachusetts, North Carolina, Michigan and Pennsylvania. The company doubled its U.S. sales territories from four to eight and aims for 12 by year-end, signed a distribution agreement with Lovell Government Services to access over 2,000 federal healthcare facilities, and partnered with Sanmina to establish a second manufacturing site. Israel granted marketing clearance, becoming the second jurisdiction and first outside the U.S. to approve LIBERTY. Cost of revenue increased quarter-over-quarter, but the company is implementing cost reduction initiatives after completing its Limited Market Release.
Microbot Medical (Nasdaq: MBOT) will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, FL, from July 23-26, 2026, showcasing its LIBERTY Endovascular Robotic System within the conference’s focus on novel robotic technologies and digital surgery applications.
The company highlights that endovascular robotics was first featured at SRS last year and notes its FDA clearance for LIBERTY less than a year ago, alongside growing adoption at leading U.S. academic centers for peripheral endovascular procedures. A panel titled “Neurovascular Robotics” will be held on Saturday, July 25, at 9:50am ET, moderated by Dr. Adnan Siddiqui. CEO, President and Chairman Harel Gadot will present an overview of the endovascular robotic market at 10:25am ET, livestreamed via the SRS 2026 platform. Microbot Medical will appear with other medical robotics companies covering peripheral vascular, neurovascular and cardiovascular technologies, and notes that LIBERTY recently received the Innovative Start-Up Award from Surgical Robotics Technology.
Microbot Medical (Nasdaq: MBOT) reported greater than 100% quarter-over-quarter growth in revenue and new customers for Q2 2026 following the Full Market Release of the LIBERTY Endovascular Robotic System on April 13, 2026.
The company expanded U.S. sales territories from 4 to 8, plans 12 by year-end, signed a distribution agreement with Lovell Government Services for federal healthcare systems, gained marketing clearance in Israel, and agreed to establish a second manufacturing site to support demand and potential margin expansion.
Microbot Medical (Nasdaq: MBOT) signed a Letter of Agreement with Sanmina to manufacture the LIBERTY Endovascular Robotic System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
The deal adds a second manufacturing site, aimed at boosting capacity, supporting global expansion, and, according to Microbot, improving operating efficiencies, lowering costs, and expanding gross margins as LIBERTY adoption grows in the U.S. and internationally.